FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3–CCL2 Signaling
Cancer-associated fibroblasts (CAF) are components of the tumor microenvironment whose contributions to malignant progression are not fully understood. Here, we show that the fibroblast activation protein (FAP) triggers induction of a CAF subset with an inflammatory phenotype directed by STAT3 activ...
Saved in:
| Published in | Cancer research (Chicago, Ill.) Vol. 76; no. 14; pp. 4124 - 4135 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
15.07.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Cancer-associated fibroblasts (CAF) are components of the tumor microenvironment whose contributions to malignant progression are not fully understood. Here, we show that the fibroblast activation protein (FAP) triggers induction of a CAF subset with an inflammatory phenotype directed by STAT3 activation and inflammation-associated expression signature marked by CCL2 upregulation. Enforcing FAP expression in normal fibroblasts was sufficient to endow them with an inflammatory phenotype similar to FAP+CAFs. We identified FAP as a persistent activator of fibroblastic STAT3 through a uPAR-dependent FAK–Src–JAK2 signaling pathway. In a murine liver tumor model, we found that FAP+CAFs were a major source of CCL2 and that fibroblastic STAT3–CCL2 signaling in this setting promoted tumor growth by enhancing recruitment of myeloid-derived suppressor cells (MDSC). The CCL2 receptor CCR2 was expressed on circulating MDSCs in tumor-bearing subjects and FAP+CAF-mediated tumor promotion and MDSC recruitment was abrogated in Ccr2-deficient mice. Clinically, we observed a positive correlation between stromal expression of FAP, p-STAT3, and CCL2 in human intrahepatic cholangiocarcinoma, a highly aggressive liver cancer with dense desmoplastic stroma, where elevated levels of stromal FAP predicted a poor survival outcome. Taken together, our results showed how FAP–STAT3–CCL2 signaling in CAFs was sufficient to program an inflammatory component of the tumor microenvironment, which may have particular significance in desmoplasia-associated cancers. Cancer Res; 76(14); 4124–35. ©2016 AACR. |
|---|---|
| AbstractList | These results illuminate how a subset of cancer-associated fibroblasts can be programmed to contribute to an inflammatory tumor microenvironment, a feature of possible great importance in desmoplasia-associated cancers. Cancer-associated fibroblasts (CAF) are components of the tumor microenvironment whose contributions to malignant progression are not fully understood. Here, we show that the fibroblast activation protein (FAP) triggers induction of a CAF subset with an inflammatory phenotype directed by STAT3 activation and inflammation-associated expression signature marked by CCL2 upregulation. Enforcing FAP expression in normal fibroblasts was sufficient to endow them with an inflammatory phenotype similar to FAP+CAFs. We identified FAP as a persistent activator of fibroblastic STAT3 through a uPAR-dependent FAK-Src-JAK2 signaling pathway. In a murine liver tumor model, we found that FAP+CAFs were a major source of CCL2 and that fibroblastic STAT3-CCL2 signaling in this setting promoted tumor growth by enhancing recruitment of myeloid-derived suppressor cells (MDSC). The CCL2 receptor CCR2 was expressed on circulating MDSCs in tumor-bearing subjects and FAP+CAF-mediated tumor promotion and MDSC recruitment was abrogated in Ccr2-deficient mice. Clinically, we observed a positive correlation between stromal expression of FAP, p-STAT3, and CCL2 in human intrahepatic cholangiocarcinoma, a highly aggressive liver cancer with dense desmoplastic stroma, where elevated levels of stromal FAP predicted a poor survival outcome. Taken together, our results showed how FAP-STAT3-CCL2 signaling in CAFs was sufficient to program an inflammatory component of the tumor microenvironment, which may have particular significance in desmoplasia-associated cancers. Cancer Res; 76(14); 4124-35. [copy2016 AACR. Cancer-associated fibroblasts (CAF) are components of the tumor microenvironment whose contributions to malignant progression are not fully understood. Here, we show that the fibroblast activation protein (FAP) triggers induction of a CAF subset with an inflammatory phenotype directed by STAT3 activation and inflammation-associated expression signature marked by CCL2 upregulation. Enforcing FAP expression in normal fibroblasts was sufficient to endow them with an inflammatory phenotype similar to FAP(+)CAFs. We identified FAP as a persistent activator of fibroblastic STAT3 through a uPAR-dependent FAK-Src-JAK2 signaling pathway. In a murine liver tumor model, we found that FAP(+)CAFs were a major source of CCL2 and that fibroblastic STAT3-CCL2 signaling in this setting promoted tumor growth by enhancing recruitment of myeloid-derived suppressor cells (MDSC). The CCL2 receptor CCR2 was expressed on circulating MDSCs in tumor-bearing subjects and FAP(+)CAF-mediated tumor promotion and MDSC recruitment was abrogated in Ccr2-deficient mice. Clinically, we observed a positive correlation between stromal expression of FAP, p-STAT3, and CCL2 in human intrahepatic cholangiocarcinoma, a highly aggressive liver cancer with dense desmoplastic stroma, where elevated levels of stromal FAP predicted a poor survival outcome. Taken together, our results showed how FAP-STAT3-CCL2 signaling in CAFs was sufficient to program an inflammatory component of the tumor microenvironment, which may have particular significance in desmoplasia-associated cancers. Cancer Res; 76(14); 4124-35. ©2016 AACR. Cancer-associated fibroblasts (CAF) are components of the tumor microenvironment whose contributions to malignant progression are not fully understood. Here, we show that the fibroblast activation protein (FAP) triggers induction of a CAF subset with an inflammatory phenotype directed by STAT3 activation and inflammation-associated expression signature marked by CCL2 upregulation. Enforcing FAP expression in normal fibroblasts was sufficient to endow them with an inflammatory phenotype similar to FAP(+)CAFs. We identified FAP as a persistent activator of fibroblastic STAT3 through a uPAR-dependent FAK-Src-JAK2 signaling pathway. In a murine liver tumor model, we found that FAP(+)CAFs were a major source of CCL2 and that fibroblastic STAT3-CCL2 signaling in this setting promoted tumor growth by enhancing recruitment of myeloid-derived suppressor cells (MDSC). The CCL2 receptor CCR2 was expressed on circulating MDSCs in tumor-bearing subjects and FAP(+)CAF-mediated tumor promotion and MDSC recruitment was abrogated in Ccr2-deficient mice. Clinically, we observed a positive correlation between stromal expression of FAP, p-STAT3, and CCL2 in human intrahepatic cholangiocarcinoma, a highly aggressive liver cancer with dense desmoplastic stroma, where elevated levels of stromal FAP predicted a poor survival outcome. Taken together, our results showed how FAP-STAT3-CCL2 signaling in CAFs was sufficient to program an inflammatory component of the tumor microenvironment, which may have particular significance in desmoplasia-associated cancers. Cancer Res; 76(14); 4124-35. ©2016 AACR.Cancer-associated fibroblasts (CAF) are components of the tumor microenvironment whose contributions to malignant progression are not fully understood. Here, we show that the fibroblast activation protein (FAP) triggers induction of a CAF subset with an inflammatory phenotype directed by STAT3 activation and inflammation-associated expression signature marked by CCL2 upregulation. Enforcing FAP expression in normal fibroblasts was sufficient to endow them with an inflammatory phenotype similar to FAP(+)CAFs. We identified FAP as a persistent activator of fibroblastic STAT3 through a uPAR-dependent FAK-Src-JAK2 signaling pathway. In a murine liver tumor model, we found that FAP(+)CAFs were a major source of CCL2 and that fibroblastic STAT3-CCL2 signaling in this setting promoted tumor growth by enhancing recruitment of myeloid-derived suppressor cells (MDSC). The CCL2 receptor CCR2 was expressed on circulating MDSCs in tumor-bearing subjects and FAP(+)CAF-mediated tumor promotion and MDSC recruitment was abrogated in Ccr2-deficient mice. Clinically, we observed a positive correlation between stromal expression of FAP, p-STAT3, and CCL2 in human intrahepatic cholangiocarcinoma, a highly aggressive liver cancer with dense desmoplastic stroma, where elevated levels of stromal FAP predicted a poor survival outcome. Taken together, our results showed how FAP-STAT3-CCL2 signaling in CAFs was sufficient to program an inflammatory component of the tumor microenvironment, which may have particular significance in desmoplasia-associated cancers. Cancer Res; 76(14); 4124-35. ©2016 AACR. |
| Author | Liu, Weiren Dang, Yongjun He, Rui Lin, Yuli Chu, Yiwei Fan, Jia Li, Bingji Shi, Yinghong Yang, Xuguang Yin, Wei |
| Author_xml | – sequence: 1 givenname: Xuguang surname: Yang fullname: Yang, Xuguang – sequence: 2 givenname: Yuli surname: Lin fullname: Lin, Yuli – sequence: 3 givenname: Yinghong surname: Shi fullname: Shi, Yinghong – sequence: 4 givenname: Bingji surname: Li fullname: Li, Bingji – sequence: 5 givenname: Weiren surname: Liu fullname: Liu, Weiren – sequence: 6 givenname: Wei surname: Yin fullname: Yin, Wei – sequence: 7 givenname: Yongjun surname: Dang fullname: Dang, Yongjun – sequence: 8 givenname: Yiwei surname: Chu fullname: Chu, Yiwei – sequence: 9 givenname: Jia surname: Fan fullname: Fan, Jia – sequence: 10 givenname: Rui surname: He fullname: He, Rui |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27216177$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc1u1DAURi3Uik5bHgHkJZsU_8Rjj1hFUYdWGmilDmvLcW6KUWIPtlPRHe_AG_ZJ8KgtCxaoK-tK57tX_s4xOvDBA0JvKTmjVKgPhBBViVqys7b5UlFRsZXkr9CCCq4qWdfiAC3-MkfoOKXvZRSUiNfoiElGl1TKBfq5bq7xdQxTyJDw5TTNPqR5t4uQkgsed_e4Nd5CrJqUgnUmQ4_XrouhG03KCTuP8zfA23kKEX92Ngbwdy4GP4HP-M4ZfLNttvzh1--23TB84269GZ2_PUWHgxkTvHl6T9DX9fm2vag2V58u22ZT2ZqoXPElYaslAWkH1pMajFmBsfWSDpSB5GANGTpprOwtY1Kx8nvRqbo3g-qVIAM_Qe8f9-5i-DFDynpyycI4Gg9hTpoqzlgtRK1egDJOeOlQFPTdEzp3E_R6F91k4r1-LrYAHx-BUkhKEQZtXTa5VJqjcaOmRO816r0ivVeki0ZNhd5rLGnxT_r5wP9zfwAegaG_ |
| CitedBy_id | crossref_primary_10_1016_j_acra_2024_07_032 crossref_primary_10_1371_journal_pone_0205918 crossref_primary_10_1016_j_tranon_2024_102023 crossref_primary_10_3390_cancers14061519 crossref_primary_10_1002_adtp_202200020 crossref_primary_10_1016_j_trsl_2019_02_006 crossref_primary_10_3390_cancers13215414 crossref_primary_10_3389_fimmu_2022_904137 crossref_primary_10_1111_imr_12978 crossref_primary_10_1186_s12943_024_01990_4 crossref_primary_10_20517_2394_5079_2023_94 crossref_primary_10_1002_cam4_5491 crossref_primary_10_1158_0008_5472_CAN_20_2339 crossref_primary_10_3389_fonc_2021_668349 crossref_primary_10_1016_j_bbcan_2025_189264 crossref_primary_10_1021_acs_molpharmaceut_1c00455 crossref_primary_10_1038_s41419_024_07270_9 crossref_primary_10_3389_fimmu_2022_1057932 crossref_primary_10_1186_s13014_022_02038_x crossref_primary_10_3389_fcell_2021_668164 crossref_primary_10_3390_cancers16183215 crossref_primary_10_1007_s00259_024_06809_4 crossref_primary_10_4103_jmau_jmau_127_23 crossref_primary_10_1186_s12929_022_00894_z crossref_primary_10_1038_s41388_022_02288_9 crossref_primary_10_1186_s40164_023_00471_6 crossref_primary_10_1007_s00280_018_3682_9 crossref_primary_10_3390_ijms242115520 crossref_primary_10_1038_s41467_024_45595_3 crossref_primary_10_1158_0008_5472_CAN_17_1915 crossref_primary_10_1093_jnci_djac178 crossref_primary_10_7717_peerj_8067 crossref_primary_10_3389_fimmu_2019_01835 crossref_primary_10_3390_cells11213369 crossref_primary_10_3390_cells14060403 crossref_primary_10_3390_ijms21218412 crossref_primary_10_1016_j_trecan_2023_01_007 crossref_primary_10_2147_JHC_S381764 crossref_primary_10_1016_j_jcmgh_2022_12_005 crossref_primary_10_1186_s12885_024_12190_0 crossref_primary_10_1186_s12964_021_00796_x crossref_primary_10_1016_j_bbcan_2023_188945 crossref_primary_10_1152_physrev_00048_2019 crossref_primary_10_3389_fcell_2023_1089068 crossref_primary_10_1158_1078_0432_CCR_17_2033 crossref_primary_10_1089_omi_2020_0023 crossref_primary_10_1016_j_canlet_2022_215611 crossref_primary_10_1158_1078_0432_CCR_22_1031 crossref_primary_10_1038_s41598_019_54791_x crossref_primary_10_1186_s12876_023_03012_x crossref_primary_10_1186_s12964_023_01151_y crossref_primary_10_1016_j_matbio_2017_12_003 crossref_primary_10_3892_mmr_2022_12687 crossref_primary_10_1016_j_omto_2021_01_011 crossref_primary_10_2217_nnm_2023_0088 crossref_primary_10_1172_JCI157399 crossref_primary_10_2139_ssrn_3575119 crossref_primary_10_3389_fonc_2020_00979 crossref_primary_10_3390_cancers13236005 crossref_primary_10_1016_j_celrep_2018_12_015 crossref_primary_10_1186_s12967_021_02987_z crossref_primary_10_1007_s00262_023_03568_3 crossref_primary_10_1016_j_kint_2022_08_036 crossref_primary_10_1038_s41467_018_05346_7 crossref_primary_10_1186_s40880_019_0427_z crossref_primary_10_1016_j_xcrm_2024_101549 crossref_primary_10_3390_cells11162618 crossref_primary_10_1021_acs_jmedchem_1c01010 crossref_primary_10_3389_fgene_2022_1067524 crossref_primary_10_3390_ijms20061263 crossref_primary_10_1039_D4CS00636D crossref_primary_10_1111_jcmm_14745 crossref_primary_10_1186_s13046_020_01637_4 crossref_primary_10_3389_fimmu_2021_795372 crossref_primary_10_1186_s12951_024_02452_1 crossref_primary_10_3390_cancers12113184 crossref_primary_10_1038_cgt_2016_65 crossref_primary_10_1016_j_ccell_2024_03_009 crossref_primary_10_1016_j_arr_2024_102296 crossref_primary_10_3390_ijms21239328 crossref_primary_10_1186_s13046_022_02340_2 crossref_primary_10_1016_j_drup_2024_101125 crossref_primary_10_3390_cancers13112850 crossref_primary_10_54097_hset_v30i_4943 crossref_primary_10_1007_s13402_023_00872_z crossref_primary_10_1002_adhm_202500176 crossref_primary_10_1016_j_ijpharm_2021_120333 crossref_primary_10_3390_ijms22168530 crossref_primary_10_18632_aging_204707 crossref_primary_10_2174_0929867329666220620124138 crossref_primary_10_1038_s41419_017_0133_1 crossref_primary_10_1089_omi_2016_0159 crossref_primary_10_1186_s13046_019_1250_8 crossref_primary_10_2217_fon_2017_0054 crossref_primary_10_1007_s00432_021_03778_1 crossref_primary_10_1007_s10555_020_09909_3 crossref_primary_10_1172_jci_insight_155300 crossref_primary_10_1007_s00259_023_06144_0 crossref_primary_10_1080_14728222_2021_1882998 crossref_primary_10_1155_2023_2480493 crossref_primary_10_1096_fj_201900578RR crossref_primary_10_1016_j_ccell_2022_09_015 crossref_primary_10_1158_1078_0432_CCR_22_3653 crossref_primary_10_1038_s41388_021_02172_y crossref_primary_10_1007_s11596_023_2740_7 crossref_primary_10_3389_fonc_2022_977618 crossref_primary_10_1007_s12032_022_01842_5 crossref_primary_10_1021_acs_jmedchem_4c01467 crossref_primary_10_1111_hel_12538 crossref_primary_10_1016_j_smim_2018_01_002 crossref_primary_10_1186_s12943_023_01860_5 crossref_primary_10_1016_j_biopha_2024_117045 crossref_primary_10_1080_15384047_2019_1617566 crossref_primary_10_1158_2159_8290_CD_20_1808 crossref_primary_10_1016_j_smim_2020_101417 crossref_primary_10_1111_cpr_13115 crossref_primary_10_1080_14712598_2022_2013799 crossref_primary_10_3389_fimmu_2023_1194642 crossref_primary_10_3389_fphar_2023_1113378 crossref_primary_10_1016_j_euo_2023_02_011 crossref_primary_10_1007_s00259_022_05729_5 crossref_primary_10_1007_s00432_021_03612_8 crossref_primary_10_1002_mog2_68 crossref_primary_10_3390_cancers16020449 crossref_primary_10_3389_fchem_2021_640566 crossref_primary_10_1038_s41416_025_02981_y crossref_primary_10_1038_s43587_024_00751_8 crossref_primary_10_3390_cells9092027 crossref_primary_10_1016_j_canlet_2021_06_009 crossref_primary_10_1111_cpr_13592 crossref_primary_10_1016_j_trecan_2019_09_009 crossref_primary_10_1111_cas_15609 crossref_primary_10_3390_ijms222010973 crossref_primary_10_1158_2326_6066_CIR_20_0111 crossref_primary_10_1016_j_jare_2024_05_031 crossref_primary_10_3389_fimmu_2021_767939 crossref_primary_10_1016_j_cyto_2017_03_018 crossref_primary_10_3389_fonc_2022_969731 crossref_primary_10_1007_s00259_023_06137_z crossref_primary_10_1016_j_ajpath_2020_01_004 crossref_primary_10_1097_MOG_0000000000000609 crossref_primary_10_3390_ijms231810869 crossref_primary_10_1016_j_phrs_2021_106036 crossref_primary_10_3390_cancers14153570 crossref_primary_10_3390_cells10051142 crossref_primary_10_3389_fonc_2021_620688 crossref_primary_10_3390_cells13121057 crossref_primary_10_1016_j_cytogfr_2019_10_005 crossref_primary_10_1002_cac2_12156 crossref_primary_10_1097_MOG_0000000000000613 crossref_primary_10_1002_ijc_32521 crossref_primary_10_1016_j_bioorg_2018_11_011 crossref_primary_10_1016_j_intimp_2024_113568 crossref_primary_10_1038_s41421_023_00529_z crossref_primary_10_3390_cells13121071 crossref_primary_10_1038_s41575_022_00741_4 crossref_primary_10_7554_eLife_57243 crossref_primary_10_1007_s13402_023_00816_7 crossref_primary_10_1007_s11912_025_01646_6 crossref_primary_10_1038_s41573_018_0004_1 crossref_primary_10_1016_j_joms_2016_09_052 crossref_primary_10_1186_s12935_023_03073_8 crossref_primary_10_2147_OTT_S257529 crossref_primary_10_1200_EDBK_390290 crossref_primary_10_2174_1871530322666220127113752 crossref_primary_10_1016_j_omton_2024_200817 crossref_primary_10_1038_s41467_023_39762_1 crossref_primary_10_3389_fonc_2023_1068405 crossref_primary_10_1038_s41388_018_0275_3 crossref_primary_10_1016_j_ccell_2017_10_005 crossref_primary_10_3390_ijms252413296 crossref_primary_10_1111_cas_15507 crossref_primary_10_1186_s13046_021_01949_z crossref_primary_10_1016_j_envpol_2024_124311 crossref_primary_10_3390_cancers12082215 crossref_primary_10_1080_1061186X_2024_2445772 crossref_primary_10_1186_s13045_024_01634_6 crossref_primary_10_1186_s13059_024_03428_y crossref_primary_10_1186_s12964_025_02033_1 crossref_primary_10_1016_j_isci_2023_106381 crossref_primary_10_1038_s41416_020_01201_z crossref_primary_10_1371_journal_pone_0171194 crossref_primary_10_3390_cancers15153898 crossref_primary_10_1073_pnas_2303075120 crossref_primary_10_1186_s13046_021_01893_y crossref_primary_10_3748_wjg_v28_i27_3297 crossref_primary_10_1007_s12094_021_02734_2 crossref_primary_10_1038_s41575_020_0310_z crossref_primary_10_1016_j_ygyno_2025_01_010 crossref_primary_10_3390_biology13110860 crossref_primary_10_1002_jcp_31278 crossref_primary_10_3390_diagnostics13203199 crossref_primary_10_1038_s41374_018_0185_6 crossref_primary_10_1186_s40164_024_00505_7 crossref_primary_10_1186_s12943_019_0979_1 crossref_primary_10_2174_0115680096267791231115101107 crossref_primary_10_1158_0008_5472_CAN_16_2379 crossref_primary_10_1158_2159_8290_CD_19_1384 crossref_primary_10_1002_psp4_13065 crossref_primary_10_1172_jci_insight_92232 crossref_primary_10_3389_fmolb_2023_1111511 crossref_primary_10_1016_j_clicom_2023_11_002 crossref_primary_10_3390_cancers15041193 crossref_primary_10_1007_s12149_021_01673_w crossref_primary_10_1016_j_intimp_2017_10_002 crossref_primary_10_1186_s13046_023_02887_8 crossref_primary_10_1016_j_intimp_2024_113001 crossref_primary_10_3389_fonc_2021_724104 crossref_primary_10_3389_fimmu_2021_771210 crossref_primary_10_3390_ijms20215400 crossref_primary_10_3390_cancers14163994 crossref_primary_10_1016_j_semcancer_2017_06_001 crossref_primary_10_1111_bph_16028 crossref_primary_10_1002_jcb_26133 crossref_primary_10_1021_acs_bioconjchem_9b00206 crossref_primary_10_1186_s12964_023_01204_2 crossref_primary_10_3389_fphar_2023_1303913 crossref_primary_10_3389_fimmu_2020_01371 crossref_primary_10_1186_s12967_023_03897_y crossref_primary_10_1042_ETLS20170068 crossref_primary_10_1038_s41568_022_00530_w crossref_primary_10_1016_j_cellsig_2023_111016 crossref_primary_10_3389_fimmu_2023_1280601 crossref_primary_10_1186_s13578_020_00488_y crossref_primary_10_1016_j_humpath_2018_03_006 crossref_primary_10_18632_oncotarget_16274 crossref_primary_10_1016_j_semcancer_2019_09_022 crossref_primary_10_1016_j_cellsig_2024_111584 crossref_primary_10_1042_CS20191211 crossref_primary_10_3390_cancers16091772 crossref_primary_10_1038_s41577_021_00540_z crossref_primary_10_3390_pharmaceutics14061202 crossref_primary_10_1002_cac2_12291 crossref_primary_10_1186_s12943_019_1117_9 crossref_primary_10_1016_j_canlet_2023_216234 crossref_primary_10_1038_s41467_024_47068_z crossref_primary_10_1111_pcmr_12657 crossref_primary_10_1158_1535_7163_MCT_23_0726 crossref_primary_10_3390_cancers13235873 crossref_primary_10_3390_ijms242316771 crossref_primary_10_3390_curroncol30040319 crossref_primary_10_1038_s41571_021_00546_5 crossref_primary_10_3389_fimmu_2023_1337333 crossref_primary_10_1016_j_jhep_2020_11_037 crossref_primary_10_3389_fimmu_2018_00414 crossref_primary_10_3389_fonc_2021_648187 crossref_primary_10_1021_acsbiomaterials_1c01131 crossref_primary_10_2147_OTT_S243417 crossref_primary_10_1021_acsnano_8b07830 crossref_primary_10_1186_s12943_021_01428_1 crossref_primary_10_1002_jcp_26433 crossref_primary_10_1016_j_jaci_2025_01_047 crossref_primary_10_1038_s41416_021_01569_6 crossref_primary_10_1016_j_trecan_2022_03_001 crossref_primary_10_3389_fimmu_2024_1433679 crossref_primary_10_3389_fcell_2023_1056964 crossref_primary_10_1002_hep_32099 crossref_primary_10_1080_14728222_2017_1370455 crossref_primary_10_1016_j_lungcan_2018_10_021 crossref_primary_10_2174_2212796814999200925162943 crossref_primary_10_1016_j_semcancer_2020_05_009 crossref_primary_10_3389_fonc_2020_589601 crossref_primary_10_1002_hed_25101 crossref_primary_10_1016_j_canlet_2017_07_006 crossref_primary_10_1016_j_gene_2024_148286 crossref_primary_10_1016_j_jcmgh_2024_101377 crossref_primary_10_1074_mcp_RA118_001046 crossref_primary_10_1111_bph_16505 crossref_primary_10_1038_s41419_021_03823_4 crossref_primary_10_1038_s41467_018_03348_z crossref_primary_10_3390_biomedicines11072017 crossref_primary_10_3390_vaccines9060634 crossref_primary_10_4049_jimmunol_2001203 crossref_primary_10_1016_j_smim_2021_101474 crossref_primary_10_3390_jcm10132889 crossref_primary_10_2967_jnumed_122_264638 crossref_primary_10_2174_0109298673282799231211113347 crossref_primary_10_1038_s41419_022_05320_8 crossref_primary_10_1002_jmri_27648 crossref_primary_10_1111_1759_7714_15398 crossref_primary_10_1038_s41568_018_0090_8 crossref_primary_10_1016_j_phymed_2023_155208 crossref_primary_10_1016_j_prp_2023_154633 crossref_primary_10_1186_s12967_023_04080_z crossref_primary_10_1111_jcmm_16556 crossref_primary_10_3389_fimmu_2022_832418 crossref_primary_10_3389_fmolb_2023_1129831 crossref_primary_10_1002_adma_202103114 crossref_primary_10_1002_oby_23955 crossref_primary_10_1007_s13258_022_01318_w crossref_primary_10_3390_ijms23073426 crossref_primary_10_1016_j_bbcan_2020_188444 crossref_primary_10_1158_1078_0432_CCR_23_3841 crossref_primary_10_1186_s13578_024_01201_z crossref_primary_10_1038_s41598_023_28480_9 crossref_primary_10_1016_j_coi_2020_03_004 crossref_primary_10_1158_1078_0432_CCR_20_2298 crossref_primary_10_1186_s12943_022_01656_z crossref_primary_10_1007_s10238_024_01375_3 crossref_primary_10_3390_cancers12102969 crossref_primary_10_3390_cancers13143526 crossref_primary_10_1016_j_addr_2022_114504 crossref_primary_10_1016_j_bmcl_2020_127253 crossref_primary_10_1080_13543784_2020_1740680 crossref_primary_10_3390_cancers14163906 crossref_primary_10_1007_s00109_023_02360_1 crossref_primary_10_1038_s41590_024_02068_5 crossref_primary_10_1038_s41392_024_01868_3 crossref_primary_10_2174_1568026623666230201145909 crossref_primary_10_3389_fonc_2020_00165 crossref_primary_10_1186_s12943_020_01258_7 crossref_primary_10_1016_j_cellsig_2022_110275 crossref_primary_10_3389_fonc_2022_984817 crossref_primary_10_1016_j_isci_2019_07_034 crossref_primary_10_1158_1078_0432_CCR_20_4226 crossref_primary_10_3389_fphar_2023_1336685 crossref_primary_10_1002_mc_23782 crossref_primary_10_1016_j_bbrc_2017_03_039 crossref_primary_10_1016_j_jcmgh_2023_01_006 crossref_primary_10_1016_j_canlet_2021_01_013 crossref_primary_10_1016_j_cis_2021_102509 crossref_primary_10_1016_j_pan_2020_02_006 crossref_primary_10_3389_fcell_2021_754069 crossref_primary_10_1007_s12094_024_03492_7 crossref_primary_10_1007_s12094_024_03723_x crossref_primary_10_1038_s41388_023_02793_5 crossref_primary_10_1126_scitranslmed_abp9229 crossref_primary_10_1080_07357907_2023_2237576 crossref_primary_10_1186_s12951_021_01172_0 crossref_primary_10_1007_s12079_021_00621_7 crossref_primary_10_1038_s41388_018_0379_9 crossref_primary_10_1053_j_gastro_2024_05_005 crossref_primary_10_1016_j_vaccine_2019_06_012 crossref_primary_10_1016_j_intimp_2023_110601 crossref_primary_10_1016_j_jbc_2025_108330 crossref_primary_10_1186_s12885_020_07541_6 crossref_primary_10_1007_s11064_017_2449_8 crossref_primary_10_4103_jofs_jofs_17_23 crossref_primary_10_1016_j_apsb_2023_11_002 crossref_primary_10_18632_aging_205205 crossref_primary_10_1158_2159_8290_CD_20_1484 crossref_primary_10_1016_j_intimp_2023_110837 crossref_primary_10_1080_14740338_2022_2020243 crossref_primary_10_3389_fendo_2023_1201755 crossref_primary_10_1155_2019_3690561 crossref_primary_10_1186_s12885_018_5035_9 crossref_primary_10_1016_j_biopha_2020_110369 crossref_primary_10_3389_fonc_2022_924223 crossref_primary_10_1016_j_ijbiomac_2024_131560 crossref_primary_10_1016_j_pharmthera_2019_04_004 crossref_primary_10_1136_jitc_2022_005627 crossref_primary_10_1016_j_isci_2021_102757 crossref_primary_10_1186_s12967_021_03112_w crossref_primary_10_1111_febs_15851 crossref_primary_10_1158_2326_6066_CIR_19_0796 crossref_primary_10_1016_j_intimp_2022_109329 crossref_primary_10_1172_JCI157649 crossref_primary_10_1053_j_gastro_2018_12_044 crossref_primary_10_1002_mc_23205 crossref_primary_10_32604_or_2024_046965 crossref_primary_10_1002_mc_23445 crossref_primary_10_3390_cancers11081172 crossref_primary_10_3389_fimmu_2021_671595 crossref_primary_10_1016_j_neo_2019_10_005 crossref_primary_10_1016_j_mtbio_2023_100702 crossref_primary_10_3389_fonc_2021_722916 crossref_primary_10_3390_cells12060846 crossref_primary_10_1038_s43018_023_00526_x crossref_primary_10_1111_his_13219 crossref_primary_10_3390_ijms20184624 crossref_primary_10_1016_j_jconrel_2020_06_037 crossref_primary_10_3727_096504019X15555408784978 crossref_primary_10_3389_fonc_2023_1166860 crossref_primary_10_1080_2162402X_2020_1747350 crossref_primary_10_1016_j_biopha_2023_115513 crossref_primary_10_1186_s40644_023_00598_z crossref_primary_10_3389_fcell_2020_621070 crossref_primary_10_3390_cancers16203542 crossref_primary_10_3390_cancers15225491 crossref_primary_10_1016_j_talanta_2024_126475 crossref_primary_10_3389_fendo_2022_988295 crossref_primary_10_1016_j_yexcr_2023_113492 crossref_primary_10_1038_s41575_019_0115_0 crossref_primary_10_3390_cancers13040697 crossref_primary_10_3390_jcm11216498 crossref_primary_10_3390_ijms242216505 crossref_primary_10_1007_s11684_023_1050_6 crossref_primary_10_1016_j_ccell_2018_01_011 crossref_primary_10_1186_s12929_024_01099_2 crossref_primary_10_1016_j_biopha_2023_115622 crossref_primary_10_1016_j_canlet_2025_217475 crossref_primary_10_1016_j_jconrel_2025_01_078 crossref_primary_10_1002_jev2_70055 crossref_primary_10_1289_EHP12259 crossref_primary_10_3390_cancers14133293 crossref_primary_10_3390_biomedicines10030713 crossref_primary_10_1080_2162402X_2021_2020984 crossref_primary_10_3389_fonc_2021_802257 crossref_primary_10_1259_bjr_20220994 crossref_primary_10_3389_fonc_2022_1072739 crossref_primary_10_1016_j_compositesb_2024_111653 crossref_primary_10_1002_lci2_39 crossref_primary_10_1111_cns_14024 crossref_primary_10_1080_00365521_2019_1708449 crossref_primary_10_1158_1078_0432_CCR_24_1690 crossref_primary_10_1111_liv_14098 crossref_primary_10_1158_2159_8290_CD_23_0013 crossref_primary_10_2147_ITT_S291767 crossref_primary_10_3390_cancers12113238 crossref_primary_10_1016_j_xcrm_2024_101838 crossref_primary_10_1038_s41401_022_00953_z crossref_primary_10_1016_j_bioelechem_2025_108917 crossref_primary_10_1038_s41467_022_30306_7 crossref_primary_10_3389_fcell_2021_729941 crossref_primary_10_1016_j_mrgentox_2024_503807 crossref_primary_10_3892_ol_2021_13144 crossref_primary_10_1007_s00428_024_03922_5 crossref_primary_10_1080_09553002_2018_1439193 crossref_primary_10_2217_imt_2020_0066 crossref_primary_10_1080_08977194_2022_2087520 crossref_primary_10_1186_s12885_020_07495_9 crossref_primary_10_3390_cancers13030405 crossref_primary_10_1186_s12935_022_02763_z crossref_primary_10_1016_j_jare_2024_01_033 crossref_primary_10_1016_j_cels_2021_08_010 crossref_primary_10_3390_vaccines9050422 crossref_primary_10_1016_j_matbio_2024_10_007 crossref_primary_10_1016_j_ymthe_2020_09_034 crossref_primary_10_1038_s41392_023_01728_6 crossref_primary_10_1007_s12672_024_01156_0 crossref_primary_10_3389_fmicb_2024_1287077 crossref_primary_10_1002_adma_202301257 crossref_primary_10_1016_j_yexmp_2017_12_003 crossref_primary_10_3390_cancers12082190 crossref_primary_10_3390_cancers16030559 crossref_primary_10_1111_cpr_13428 crossref_primary_10_1038_s41556_023_01208_7 crossref_primary_10_4254_wjh_v9_i9_455 crossref_primary_10_3389_fcell_2022_957363 crossref_primary_10_1096_fj_201802226R crossref_primary_10_1016_j_phrs_2023_106914 crossref_primary_10_1016_j_hbpd_2021_08_012 crossref_primary_10_1016_j_pathol_2024_12_637 crossref_primary_10_1186_s12964_025_02138_7 crossref_primary_10_1016_j_euros_2024_06_011 crossref_primary_10_1038_s41419_023_06110_6 crossref_primary_10_1038_s41598_022_14297_5 crossref_primary_10_3389_fdmed_2023_1116402 crossref_primary_10_3389_fimmu_2022_1035276 crossref_primary_10_1016_j_trecan_2018_01_007 crossref_primary_10_1016_j_cellsig_2021_110044 crossref_primary_10_1200_JCO_24_02081 crossref_primary_10_3389_fmed_2024_1381863 crossref_primary_10_1021_acs_jmedchem_7b00767 crossref_primary_10_1186_s13045_019_0770_1 crossref_primary_10_1007_s43032_022_01064_0 crossref_primary_10_3390_cells13070560 crossref_primary_10_1186_s12885_024_12907_1 crossref_primary_10_1016_j_metabol_2020_154215 crossref_primary_10_1084_jem_20191094 crossref_primary_10_3390_ijms22147575 crossref_primary_10_3390_cancers13194932 crossref_primary_10_3389_fcell_2019_00060 crossref_primary_10_1002_adfm_202102274 crossref_primary_10_1158_1078_0432_CCR_18_0205 crossref_primary_10_1186_s40364_022_00406_z crossref_primary_10_1111_1759_7714_15193 crossref_primary_10_3389_fcell_2022_830208 crossref_primary_10_1016_j_compbiomed_2024_108537 crossref_primary_10_1016_j_jcrpr_2017_08_001 crossref_primary_10_1038_s41575_023_00821_z crossref_primary_10_3389_fonc_2022_970279 crossref_primary_10_1016_j_ctro_2020_04_001 crossref_primary_10_1038_s41568_024_00740_4 crossref_primary_10_3390_ijms22158355 crossref_primary_10_1016_j_immuni_2021_04_021 crossref_primary_10_1016_j_actbio_2021_09_003 crossref_primary_10_1016_j_cellsig_2022_110567 crossref_primary_10_1002_jcb_30172 crossref_primary_10_1002_hep_31410 |
| Cites_doi | 10.1593/neo.121850 10.1084/jem.20122344 10.1038/nrc2734 10.1038/nri3175 10.1016/j.immuni.2013.08.025 10.1073/pnas.91.12.5657 10.1038/nrc1877 10.1387/ijdb.041802ad 10.1073/pnas.1320318110 10.1084/jem.20101956 10.1038/nrm2821 10.1016/j.ccr.2014.04.021 10.4049/jimmunol.179.5.3332 10.1158/0008-5472.CAN-04-0447 10.1038/nature10138 10.1084/jem.20130110 10.1084/jem.20140692 10.1084/jem.20091474 10.1089/jir.2008.0027 10.1158/0008-5472.CAN-11-3567 10.1038/nm.2574 10.1073/pnas.1017547108 10.1158/0008-5472.CAN-14-3041 10.1093/carcin/23.10.1593 10.1016/j.ccr.2009.12.041 10.4049/jimmunol.0802740 10.1016/j.cell.2012.04.042 10.1016/j.ccr.2014.04.005 10.1073/pnas.131568898 10.1038/nature07205 10.1084/jem.20090207 10.1172/JCI38988 10.1016/j.ccr.2012.03.039 10.1097/MOG.0b013e32834405c3 10.1053/j.gastro.2014.08.039 10.1038/nri3070 10.1002/hep.510290631 10.1038/nrc3792 10.1016/j.semcancer.2013.12.010 10.1038/nature08486 10.1126/science.1195300 10.1189/jlb.0911449 10.1158/0008-5472.CAN-13-2740 |
| ContentType | Journal Article |
| Copyright | 2016 American Association for Cancer Research. |
| Copyright_xml | – notice: 2016 American Association for Cancer Research. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T5 H94 |
| DOI | 10.1158/0008-5472.CAN-15-2973 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7445 |
| EndPage | 4135 |
| ExternalDocumentID | 27216177 10_1158_0008_5472_CAN_15_2973 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ CGR CUY CVF ECM EIF NPM RHF 7X8 7T5 H94 |
| ID | FETCH-LOGICAL-c408t-3602960e7cf2d04eaa9eac461f12e73eca0fb7ac7dc227825385b84daf8d850f3 |
| ISSN | 0008-5472 1538-7445 |
| IngestDate | Thu Jul 10 19:20:04 EDT 2025 Tue Aug 05 10:19:53 EDT 2025 Wed Feb 19 02:09:24 EST 2025 Tue Jul 01 01:41:13 EDT 2025 Thu Apr 24 22:57:42 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 14 |
| Language | English |
| License | 2016 American Association for Cancer Research. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c408t-3602960e7cf2d04eaa9eac461f12e73eca0fb7ac7dc227825385b84daf8d850f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 27216177 |
| PQID | 1823030515 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_1832245548 proquest_miscellaneous_1823030515 pubmed_primary_27216177 crossref_citationtrail_10_1158_0008_5472_CAN_15_2973 crossref_primary_10_1158_0008_5472_CAN_15_2973 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-07-15 |
| PublicationDateYYYYMMDD | 2016-07-15 |
| PublicationDate_xml | – month: 07 year: 2016 text: 2016-07-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer research (Chicago, Ill.) |
| PublicationTitleAlternate | Cancer Res |
| PublicationYear | 2016 |
| References | Smith (2022061704584107000_bib21) 2010; 11 Roberts (2022061704584107000_bib43) 2013; 210 Desmouliere (2022061704584107000_bib5) 2004; 48 Shi (2022061704584107000_bib30) 2011; 11 Acharyya (2022061704584107000_bib42) 2012; 150 Kalluri (2022061704584107000_bib1) 2006; 6 Qian (2022061704584107000_bib37) 2011; 475 Christiansen (2022061704584107000_bib24) 2013; 15 Brown (2022061704584107000_bib38) 2007; 179 Mantovani (2022061704584107000_bib17) 2008; 454 Scanlan (2022061704584107000_bib11) 1994; 91 Adams (2022061704584107000_bib25) 2004; 64 Ohlund (2022061704584107000_bib2) 2014; 211 Cortez (2022061704584107000_bib9) 2014; 25 Sirica (2022061704584107000_bib31) 2011; 27 Tsuyada (2022061704584107000_bib29) 2012; 72 Deng (2022061704584107000_bib32) 2012; 21 Ozdemir (2022061704584107000_bib4) 2014; 25 Molon (2022061704584107000_bib39) 2011; 208 Osterreicher (2022061704584107000_bib10) 2011; 108 Yu (2022061704584107000_bib18) 2009; 9 Wong (2022061704584107000_bib34) 2012; 18 Sulzmaier (2022061704584107000_bib20) 2014; 14 Wan (2022061704584107000_bib36) 2014; 147 Sander (2022061704584107000_bib41) 2010; 207 Erez (2022061704584107000_bib8) 2010; 17 Cheng (2022061704584107000_bib13) 2002; 62 Cui (2022061704584107000_bib35) 2013; 39 Deshmane (2022061704584107000_bib28) 2009; 29 Santos (2022061704584107000_bib6) 2009; 119 Lo (2022061704584107000_bib14) 2015; 75 Artym (2022061704584107000_bib19) 2002; 23 Bowman (2022061704584107000_bib22) 2001; 98 Gabrilovich (2022061704584107000_bib26) 2012; 12 Ostrand-Rosenberg (2022061704584107000_bib27) 2009; 182 Augsten (2022061704584107000_bib40) 2014; 74 Rhim (2022061704584107000_bib3) 2014; 25 Kraman (2022061704584107000_bib15) 2010; 330 Tran (2022061704584107000_bib44) 2013; 210 Levy (2022061704584107000_bib12) 1999; 29 Bai (2022061704584107000_bib23) 2013; 93 Feig (2022061704584107000_bib16) 2013; 110 Wang (2022061704584107000_bib33) 2009; 206 Trimboli (2022061704584107000_bib7) 2009; 461 |
| References_xml | – volume: 15 start-page: 348 year: 2013 ident: 2022061704584107000_bib24 article-title: Targeting inhibition of fibroblast activation protein-alpha and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments publication-title: Neoplasia doi: 10.1593/neo.121850 – volume: 210 start-page: 1137 year: 2013 ident: 2022061704584107000_bib43 article-title: Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia publication-title: J Exp Med doi: 10.1084/jem.20122344 – volume: 9 start-page: 798 year: 2009 ident: 2022061704584107000_bib18 article-title: STATs in cancer inflammation and immunity: a leading role for STAT3 publication-title: Nat Rev Cancer doi: 10.1038/nrc2734 – volume: 12 start-page: 253 year: 2012 ident: 2022061704584107000_bib26 article-title: Coordinated regulation of myeloid cells by tumours publication-title: Nat Rev Immunol doi: 10.1038/nri3175 – volume: 39 start-page: 611 year: 2013 ident: 2022061704584107000_bib35 article-title: Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2 publication-title: Immunity doi: 10.1016/j.immuni.2013.08.025 – volume: 91 start-page: 5657 year: 1994 ident: 2022061704584107000_bib11 article-title: Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.91.12.5657 – volume: 6 start-page: 392 year: 2006 ident: 2022061704584107000_bib1 article-title: Fibroblasts in cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc1877 – volume: 62 start-page: 4767 year: 2002 ident: 2022061704584107000_bib13 article-title: Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model publication-title: Cancer Res – volume: 48 start-page: 509 year: 2004 ident: 2022061704584107000_bib5 article-title: The stroma reaction myofibroblast: a key player in the control of tumor cell behavior publication-title: Int J Dev Biol doi: 10.1387/ijdb.041802ad – volume: 110 start-page: 20212 year: 2013 ident: 2022061704584107000_bib16 article-title: Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1320318110 – volume: 208 start-page: 1949 year: 2011 ident: 2022061704584107000_bib39 article-title: Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells publication-title: J Exp Med doi: 10.1084/jem.20101956 – volume: 11 start-page: 23 year: 2010 ident: 2022061704584107000_bib21 article-title: Regulation of cell signalling by uPAR publication-title: Nat Rev Mol Cell Bio doi: 10.1038/nrm2821 – volume: 25 start-page: 735 year: 2014 ident: 2022061704584107000_bib3 article-title: Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.04.021 – volume: 179 start-page: 3332 year: 2007 ident: 2022061704584107000_bib38 article-title: Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells publication-title: J Immunol doi: 10.4049/jimmunol.179.5.3332 – volume: 64 start-page: 5471 year: 2004 ident: 2022061704584107000_bib25 article-title: PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-0447 – volume: 475 start-page: 222 year: 2011 ident: 2022061704584107000_bib37 article-title: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis publication-title: Nature doi: 10.1038/nature10138 – volume: 210 start-page: 1125 year: 2013 ident: 2022061704584107000_bib44 article-title: Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia publication-title: J Exp Med doi: 10.1084/jem.20130110 – volume: 211 start-page: 1503 year: 2014 ident: 2022061704584107000_bib2 article-title: Fibroblast heterogeneity in the cancer wound publication-title: J Exp Med doi: 10.1084/jem.20140692 – volume: 207 start-page: 1453 year: 2010 ident: 2022061704584107000_bib41 article-title: Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function publication-title: J Exp Med doi: 10.1084/jem.20091474 – volume: 29 start-page: 313 year: 2009 ident: 2022061704584107000_bib28 article-title: Monocyte chemoattractant protein-1 (MCP-1): an overview publication-title: J Interferon Cytokine Res doi: 10.1089/jir.2008.0027 – volume: 72 start-page: 2768 year: 2012 ident: 2022061704584107000_bib29 article-title: CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-3567 – volume: 18 start-page: 148 year: 2012 ident: 2022061704584107000_bib34 article-title: Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling publication-title: Nat Med doi: 10.1038/nm.2574 – volume: 108 start-page: 308 year: 2011 ident: 2022061704584107000_bib10 article-title: Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1017547108 – volume: 75 start-page: 2800 year: 2015 ident: 2022061704584107000_bib14 article-title: Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-3041 – volume: 23 start-page: 1593 year: 2002 ident: 2022061704584107000_bib19 article-title: Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta(1) integrins and the cytoskeleton publication-title: Carcinogenesis doi: 10.1093/carcin/23.10.1593 – volume: 17 start-page: 135 year: 2010 ident: 2022061704584107000_bib8 article-title: Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.12.041 – volume: 182 start-page: 4499 year: 2009 ident: 2022061704584107000_bib27 article-title: Myeloid-derived suppressor cells: linking inflammation and cancer publication-title: J Immunol doi: 10.4049/jimmunol.0802740 – volume: 150 start-page: 165 year: 2012 ident: 2022061704584107000_bib42 article-title: A CXCL1 paracrine network links cancer chemoresistance and metastasis publication-title: Cell doi: 10.1016/j.cell.2012.04.042 – volume: 25 start-page: 719 year: 2014 ident: 2022061704584107000_bib4 article-title: Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.04.005 – volume: 98 start-page: 7319 year: 2001 ident: 2022061704584107000_bib22 article-title: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.131568898 – volume: 454 start-page: 436 year: 2008 ident: 2022061704584107000_bib17 article-title: Cancer-related inflammation publication-title: Nature doi: 10.1038/nature07205 – volume: 206 start-page: 1457 year: 2009 ident: 2022061704584107000_bib33 article-title: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway publication-title: J Exp Med doi: 10.1084/jem.20090207 – volume: 119 start-page: 3613 year: 2009 ident: 2022061704584107000_bib6 article-title: Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice publication-title: J Clin Invest doi: 10.1172/JCI38988 – volume: 21 start-page: 642 year: 2012 ident: 2022061704584107000_bib32 article-title: S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.03.039 – volume: 27 start-page: 276 year: 2011 ident: 2022061704584107000_bib31 article-title: Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma publication-title: Curr Opin Gastroenterol doi: 10.1097/MOG.0b013e32834405c3 – volume: 147 start-page: 1393 year: 2014 ident: 2022061704584107000_bib36 article-title: Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.08.039 – volume: 11 start-page: 762 year: 2011 ident: 2022061704584107000_bib30 article-title: Monocyte recruitment during infection and inflammation publication-title: Nat Rev Immunol doi: 10.1038/nri3070 – volume: 29 start-page: 1768 year: 1999 ident: 2022061704584107000_bib12 article-title: Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis publication-title: Hepatology doi: 10.1002/hep.510290631 – volume: 14 start-page: 598 year: 2014 ident: 2022061704584107000_bib20 article-title: FAK in cancer: mechanistic findings and clinical applications publication-title: Nat Rev Cancer doi: 10.1038/nrc3792 – volume: 25 start-page: 3 year: 2014 ident: 2022061704584107000_bib9 article-title: Functional subsets of mesenchymal cell types in the tumor microenvironment publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2013.12.010 – volume: 461 start-page: 1084 year: 2009 ident: 2022061704584107000_bib7 article-title: Pten in stromal fibroblasts suppresses mammary epithelial tumours publication-title: Nature doi: 10.1038/nature08486 – volume: 330 start-page: 827 year: 2010 ident: 2022061704584107000_bib15 article-title: Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha publication-title: Science doi: 10.1126/science.1195300 – volume: 93 start-page: 101 year: 2013 ident: 2022061704584107000_bib23 article-title: Thrombin-induced CCN2 expression in human lung fibroblasts requires the c-Src/JAK2/STAT3 pathway publication-title: J Leukoc Biol doi: 10.1189/jlb.0911449 – volume: 74 start-page: 2999 year: 2014 ident: 2022061704584107000_bib40 article-title: Cancer-associated fibroblasts expressing CXCL14 Rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-2740 |
| SSID | ssj0005105 |
| Score | 2.6556714 |
| Snippet | Cancer-associated fibroblasts (CAF) are components of the tumor microenvironment whose contributions to malignant progression are not fully understood. Here,... These results illuminate how a subset of cancer-associated fibroblasts can be programmed to contribute to an inflammatory tumor microenvironment, a feature of... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 4124 |
| SubjectTerms | Animals Cancer-Associated Fibroblasts - physiology Cell Movement Chemokine CCL2 - physiology Female Focal Adhesion Protein-Tyrosine Kinases - physiology Gelatinases - physiology Immune Tolerance Janus Kinase 2 - physiology Membrane Proteins - physiology Mice Mice, Inbred C57BL Receptors, Urokinase Plasminogen Activator - physiology Serine Endopeptidases - physiology Signal Transduction - physiology STAT3 Transcription Factor - physiology Tumor Microenvironment |
| Title | FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3–CCL2 Signaling |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27216177 https://www.proquest.com/docview/1823030515 https://www.proquest.com/docview/1832245548 |
| Volume | 76 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2FIiFeEPeGmxaJN8vBl7W9PEaBqAVaIZFKyZO1Xq9bo2BXSYyAJ_6B_-Fj-BJmvOsLbSiUF8uy7F3LczyX3TMzhDwDnzt1WObYnoRIhwmR2pzDwQ9ZKL2US6dunXBwGO4dsdfzYD4Y_OixlqpNMpJft-aV_I9U4RrIFbNkLyHZdlC4AOcgXziChOH4TzKejt8h0x--tlpb-5jpUa6rU0NtLdCznKBQV3YjBPAupxAflwn4zJt1w3GcVR_LFRLoV2Uv7836lAtwGMczvyFE-JPJW896nx-j824sXlfkAOaxTOmgk3pvWJM8aiW0XI56Sw4Ls0Y9r44rYcZBTpAuZ7Colnm77lO3HLYWMNtJ2b-zhiVc_ZD3ly3cENdDdeJmq4q5HTDdt2ekOu0bMV1fslHPuj1MA0PWU7bYOLtnuMEcB9uNQsA1i1JPOJqMD-FVbOza1VnBZuf_jHFsKYt1sBRw3KznMQ4TwzCxG8Q4zBVy1YMwBTtovNx_01GMDIW2mdlkkMEwz7e-ze--0R8Cntrxmd0kN0zEQscafrfIQBW3ybUDw8m4Qz4DCmmDQnoOhTT5Qs-hkPZQSPOCAgppjUJ6FoUUUEhrFP789h3xR1v83SVH01ezyZ5t-nnYkjl8A_-_40HArCKZeaAglBAvwOyz0M1cT0W-ksLJkkjIKJWYoO0BGoKEs1RkPOWBk_n3yE5RFmqX0CAVEHlH0g_Ax3RlyBPlh0KAb6pXNIaENV8ylqbYPfZcWcYXynFIRu1jp7ray98eeNqIKQa9jJttolBltY5d3MH2sYPSRfeAOWXg0PMhua9l3E7rYVUtN4oeXPaVHpLr3f_2iOxsVpV6DI7zJnlSo_MX9G-5sA |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FAP+Promotes+Immunosuppression+by+Cancer-Associated+Fibroblasts+in+the+Tumor+Microenvironment+via+STAT3%E2%80%93CCL2+Signaling&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Yang%2C+Xuguang&rft.au=Lin%2C+Yuli&rft.au=Shi%2C+Yinghong&rft.au=Li%2C+Bingji&rft.date=2016-07-15&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=76&rft.issue=14&rft.spage=4124&rft.epage=4135&rft_id=info:doi/10.1158%2F0008-5472.CAN-15-2973&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_0008_5472_CAN_15_2973 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |